CDK9 and prostate carcinoma: CDK9 activity can be depleted using the specific inhibitor NVP2 (Olson et al. 2018), which we have shown to be effective in low nanomolar doses against prostate cancer cells (Gondane et al. 2022a, b; Hu et al. 2021).